QureBio Ltd. to Present Q-1802 PhaseⅡ Data at 2024 SITC Annual Meeting

SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- QureBio Ltd., a company at the forefront of biopharmaceutical innovation, has announced the presentation of Phase II clinical data from its Q-1802 program at the 39th annual meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, scheduled for November 8–9, 2024. The abstract (#1500) will be available during the meeting, and the detailed findings will be presented on November 9 at George R. Brown Convention Center.

The focus of the presentation is on a Phase II trial of Q-1802, a bispecific antibody, in patients with relapsed or refractory solid tumors. The authors of the study include Yakun Wang, Jifang Gong, Xiangdong Qu, and Lin Shen. Q-1802 targets both the tumor-specific antigen Claudin18 isoform 2 (CLDN18.2) and the immune checkpoint PD-L1. This dual-targeting capability is a significant advancement in cancer treatment, aiming to improve the efficacy of immunotherapy.

The clinical data revealed an impressive objective response rate (ORR) of approximately 70.0% in the 10 mg/kg dosage group. Furthermore, the safety profile of Q-1802 was favorable, with around 55% of patients experiencing Grade 3 or higher adverse events, yet none of these were fatal or above Grade 3 severity. These results underscore Q-1802's potential as a potent anti-tumor agent with manageable safety concerns.

Q-1802 stands out as the first FDA-approved bispecific antibody targeting Claudin18.2/PD-L1, and it is currently undergoing clinical trials. Its mechanism of action includes the recruitment of multiple immune responses, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). This multi-faceted approach enhances its therapeutic potential for solid tumors expressing Claudin18.2, irrespective of the expression levels.

In addition to its high affinity and selectivity, Q-1802's innovative molecular design and robust production process ensure high yield and efficiency. This makes it a promising candidate for treating a range of Claudin18.2 positive cancers.

During the SITC conference, QureBio also introduced its T-cell engage and T cell engager enhancer platforms. These platforms are instrumental in developing bispecific antibodies targeting both cancer and autoimmune diseases, showcasing the company's commitment to expanding the scope of immunotherapy.

QureBio Ltd., established in 2017 with initial funding from Viva Bio-Innovator, has grown through subsequent investments from various entities including Jundu Investment, Watson Capital, and Shenzhen Capital Group, among others. The company has secured nearly 200 million CNY in Series-B funding, reflecting strong investor confidence in its innovative approach.

As a clinical-stage biopharmaceutical firm, QureBio Ltd. focuses on developing engineered bio-macromolecules to address urgent and unmet clinical needs, particularly in the realm of refractory cancers and severe inflammatory conditions. The company leverages its proprietary technologies to create bi-specific and tri-specific antibodies, aiming to bring novel therapies to the market.

QureBio's collaborative efforts extend to several industrial partners such as BRL Medicine, Precision Scientific, and Hengrui Pharmaceuticals. These partnerships are crucial in advancing the development of new therapeutics for various medical needs.

Overall, the promising data from the Q-1802 program and the introduction of new platforms at the SITC conference highlight QureBio's significant contributions to biopharmaceutical research and its potential impact on the future of cancer and autoimmune disease treatment.